These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 35952942)

  • 21. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease.
    D'Haens G; Ferrante M; Vermeire S; Baert F; Noman M; Moortgat L; Geens P; Iwens D; Aerden I; Van Assche G; Van Olmen G; Rutgeerts P
    Inflamm Bowel Dis; 2012 Dec; 18(12):2218-24. PubMed ID: 22344983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing anorectal function in patients with recurrent ulcerative colitis.
    Wu Q; Li T; Deng F; Yao X; Chen X; Jiang Q; Ding X
    Int J Colorectal Dis; 2024 Jul; 39(1):110. PubMed ID: 39009899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Salivary Calprotectin Is not a Useful Biomarker to Monitor Disease Activity in Patients with Inflammatory Bowel Disease.
    Bos V; Crouwel F; Waaijenberg P; Bouma G; Duijvestein M; Buiter HJ; Brand HS; Hamer HM; De Boer NK
    J Gastrointestin Liver Dis; 2022 Sep; 31(3):283-289. PubMed ID: 36004414
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Response to Letter to Editor on "Reduction of Fecal Calprotectin Levels Induced by a Short Course of Escherichia Coli Nissle is Associated with a Lower Likelihood of Disease Flares in Patients with Ulcerative Colitis in Clinical Remission".
    Pasta A; Calabrese F; Bodini G
    J Gastrointestin Liver Dis; 2024 Jun; 33(2):281. PubMed ID: 38944863
    [No Abstract]   [Full Text] [Related]  

  • 25. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy.
    De Vos M; Louis EJ; Jahnsen J; Vandervoort JG; Noman M; Dewit O; Dʼhaens GR; Franchimont D; Baert FJ; Torp RA; Henriksen M; Potvin PM; Van Hootegem PP; Hindryckx PM; Moreels TG; Collard A; Karlsen LN; Kittang E; Lambrecht G; Grimstad T; Koch J; Lygren I; Coche JC; Mana F; Van Gossum A; Belaiche J; Cool MR; Fontaine F; Maisin JM; Muls V; Neuville B; Staessen DA; Van Assche GA; de Lange T; Solberg IC; Vander Cruyssen BJ; Vermeire SA
    Inflamm Bowel Dis; 2013 Sep; 19(10):2111-7. PubMed ID: 23883959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. IBS-like Symptoms in Patients with Ulcerative Colitis in Deep Remission Are Associated with Increased Levels of Serum Cytokines and Poor Psychological Well-being.
    Jonefjäll B; Öhman L; Simrén M; Strid H
    Inflamm Bowel Dis; 2016 Nov; 22(11):2630-2640. PubMed ID: 27636379
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fecal calprotectin and the clinical activity index are both useful to monitor medical treatment in patients with ulcerative colitis.
    Burri E; Beglinger C; von Felten S; Lehmann FS
    Dig Dis Sci; 2015 Feb; 60(2):485-91. PubMed ID: 25344905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse.
    Gisbert JP; Bermejo F; Pérez-Calle JL; Taxonera C; Vera I; McNicholl AG; Algaba A; López P; López-Palacios N; Calvo M; González-Lama Y; Carneros JA; Velasco M; Maté J
    Inflamm Bowel Dis; 2009 Aug; 15(8):1190-8. PubMed ID: 19291780
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive value of faecal calprotectin in ulcerative colitis - single centre experience.
    Grgić D; Golubić K; Brinar M; Krznarić Ž
    Ann Med; 2022 Dec; 54(1):1570-1577. PubMed ID: 35635011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?
    García-Sánchez V; Iglesias-Flores E; González R; Gisbert JP; Gallardo-Valverde JM; González-Galilea A; Naranjo-Rodríguez A; de Dios-Vega JF; Muntané J; Gómez-Camacho F
    J Crohns Colitis; 2010 Jun; 4(2):144-52. PubMed ID: 21122498
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High within-day variability of fecal calprotectin levels in patients with active ulcerative colitis: what is the best timing for stool sampling?
    Calafat M; Cabré E; Mañosa M; Lobatón T; Marín L; Domènech E
    Inflamm Bowel Dis; 2015 May; 21(5):1072-6. PubMed ID: 25793326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of fecal calprotectin in monitoring activity of inflammatory bowel diseases.
    Knyazev OV; Kagramanova AV; Korneeva IA; Noskova KK; Belousov SV; Parfenov AI
    Ter Arkh; 2019 May; 91(4):53-61. PubMed ID: 31094477
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of Fecal Markers with Magnifying Endoscopic Stratification in Patients with Ulcerative Colitis Who Are in Clinical Remission.
    Mine S; Takeshima F; Akazawa Y; Matsushima K; Minami H; Yamaguchi N; Ohnita K; Isomoto H; Nakao K
    Digestion; 2018; 97(1):82-89. PubMed ID: 29393146
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapid fecal calprotectin test for prediction of mucosal inflammation in ulcerative colitis and Crohn disease: a prospective cohort study.
    Moniuszko A; Głuszek S; Rydzewska G
    Pol Arch Intern Med; 2017 May; 127(5):312-318. PubMed ID: 28442699
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessing the Correlation of Fecal Calprotectin and the Clinical Disease Activity Index in Patients With Ulcerative Colitis.
    Amiriani T; Besharat S; Dadjou M; Roshandel G; Mirkarimi H; Salamat F; Joshaghani H
    Gastroenterol Nurs; 2018; 41(3):201-205. PubMed ID: 29847394
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pancreatitis-associated protein does not predict disease relapse in inflammatory bowel disease patients.
    Nunes T; Etchevers MJ; Sandi MJ; Pinó Donnay S; Grandjean T; Pellisé M; Panés J; Ricart E; Iovanna JL; Dagorn JC; Chamaillard M; Sans M
    PLoS One; 2014; 9(1):e84957. PubMed ID: 24416322
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of IBS-like symptoms in patients with ulcerative colitis in clinical remission.
    Jonefjäll B; Strid H; Ohman L; Svedlund J; Bergstedt A; Simren M
    Neurogastroenterol Motil; 2013 Sep; 25(9):756-e578. PubMed ID: 23731196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Using item response theory (IRT) to improve the efficiency of the Simple Clinical Colitis Activity Index (SCCAI) for patients with ulcerative colitis.
    Walsh A; Cao R; Wong D; Kantschuster R; Matini L; Wilson J; Kormilitzin A; South M; Travis S; Bauermeister S
    BMC Gastroenterol; 2021 Mar; 21(1):132. PubMed ID: 33752610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low Fecal Calprotectin Correlates with Histological Remission and Mucosal Healing in Ulcerative Colitis and Colonic Crohn's Disease.
    Zittan E; Kelly OB; Kirsch R; Milgrom R; Burns J; Nguyen GC; Croitoru K; Van Assche G; Silverberg MS; Steinhart AH
    Inflamm Bowel Dis; 2016 Mar; 22(3):623-30. PubMed ID: 26829408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers.
    Ricanek P; Brackmann S; Perminow G; Lyckander LG; Sponheim J; Holme O; Høie O; Rydning A; Vatn MH;
    Scand J Gastroenterol; 2011 Sep; 46(9):1081-91. PubMed ID: 21619483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.